The value of HPV L1 and NuMA1 proteins in the prediction of cervical intraepithelial neoplasia associated with high-risk human papillomavirus
Objective. To define the role of HPV L1 and NuMA1 expression in predicting cervical intraepithelial neoplasias (CIN).Ershov V.A., Lisyanskaya A.S., Ronzhina E.A., Rakhminova E.R.
Material and methods. Cervical biopsies from 138 women with cervical neoplasias associated with high-risk human papillomavirus (HR-HPV) were investigated by cytological, histological, immunocytochemical, and PCR assays.
Results. HR-HPV-positive mild (45.7%), moderate (29.7%), and severe (23.9%) forms of dysplasia, or carcinoma in situ (0.7%) were verified. Of them, there were 7.2% of pregnant women. Regression of dysplasia was noted in 61.4% of the studies of CIN with the nuclear expression of L1 and NuMA1; the persistent severity of a squamous epithelial lesion was shown in 31.8% of the studies, and progression of dysplasia was detected in 6.8%. Dysplasia regression and persistence were found in 52.2 and 47.8% of cases with CIN and NuMA1 expression, respectively. The regression, persistence, and progression of CIN were seen in 34.6, 57.7, and 7.7% of the studies of this lesion with L1 expression, respectively. Restoration of the typical structure of the cervical squamous epithelium was revealed in 71.4% of the women with the expression of L1 and NuMA1 or one of these proteins in the atypical cells during pregnancy. A control study demonstrated CIN persistence in pregnant women with no production of L1 and NuNA1 proteins by atypical cells.
Conclusion. With the atypical cells producing L1 and NuMA1 or one of these proteins, the regression, persistence, and progression of cervical squamous epithelial dysplasia were revealed in 51.6, 43.0, and 5.4% of the studies, respectively.
Keywords
cervix uteri
cervical intraepithelial neoplasia
prognosis
Supplementary Materials
- Table 1. Quantity of cases with экспрессией L1 and NuMA1 in atypical cells.
- Table 2. Results of control research CIN.
- Figure 1. Expression L1 in superficial cells squamous epithelia (at the left) and absence expression in atypical cells CIN3 (on the right). Immunocytochemical detection. ×400
- Figure 2. Expression NuMA1 in atypical cells CIN2. Immunocytochemical detection. ×400
References
1. Hernández-Hernández D.M., Apresa-García T., Patlán-Pérez R.M. Epidemiological overview of uterine cervical cancer. Rev. Med. Inst. Mex. Seguro. Soc. 2015; 53(Suppl. 2): S154-61.
2. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России; 2015. 250с. [Kaprin A.D., Starinskij V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2013 (morbidity and mortality). Moscow: FGBU “MNIOI im. P.A. Gercena” Minzdrava Rossii; 2015. 250p. (in Russian)]
3. Раннее выявление и комплексная диагностика рака шейки матки. Методические рекомендации. Л.: НИИО им. Н.Н. Петрова; 1977. 21с. [Early detection and comprehensive diagnosis of cervical cancer. Guidelines. Leningrad: NIIO im. N.N. Petrova; 1977. 21p. ( in Russian)]
4. Шиллер-Волкова Н.Н., Никитина Н.И., Агамова К.А., Брин М.Л. Цитологическая диагностика злокачественных новообразований. Атлас. М.: Медицина; 1964. 263с. [Shiller-Volkova N.N., Nikitina N.I., Agamova K.A., Brin M.L. Cytological diagnosis of malignant neoplasms. Atlas. Moscow: Meditsina; 1964. 263p. (in Russian)]
5. Costa C., Espinet B., Molina M.A., Salgado R., Salido M., Baró T. et al. Analysis of gene status in cervical dysplastic lesions and squamous cell carcinoma using tissue microarrays. Histol. Histopathol. 2009; 24(7): 821-9.
6. Киселев В.И., Муйжнек Е.Л. Молекулярные механизмы развития дисплазии шейки матки: новые знания – новые возможности. М.; 2012. 19с. [Kiselev V.I., Mujzhnek E.L. Molecular mechanisms of development of cervical dysplasia: new knowledge – new opportunities. Moscow; 2012. 19p. (in Russian)]
7. Griesser H., Sander H., Walczak C., Hilfrich R.A. HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early squamous dysplastic lesions. Am. J. Clin. Pathol. 2009; 132(6): 840-5.
8. Warren J.E., Silver R.M. Genetics of the cervix in relation to preterm birth. Semin. Perinatol. 2009; 33(5): 308-11.
9. Stemberger-Papic S., Vrdoliyak-Mozetic D., Ostojic D.V., Rubesa-Mihaliyevic R., Manestar M. Evaluation of the HPV L1 capsid protein in prognosis of mild and moderate dysplasia of the cervix uteri. Coll. Antropol. 2010; 34(2): 419-23.
10. Jung S.H., Choi Y.J., Kim M.S., Baek I.P., Lee S.H., Lee A.W. et al. Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix. Oncotarget. 2015; 6(6): 4385-93.
11. D´Ottaviano M.G., Discacciati M.G., Andreoli M.A., Costa M.C., Termini L., Rabelo-Santos S.H. et al. HPV 16 is related to the progression of cervical intraepithelial neoplasia grade 2: a case series. Obstet. Gynecol. Int. 2013; 2013: 328909.
12. Arias-Pulido H., Peyton C.L., Joste N.E., Vargas H., Wheeker C.M. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J. Clin. Microbiol. 2006; 44(5): 1755-62.
13. Xue Y., Bellanger S., Zhang W., Lim D., Low J., Lunny D. et al. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res. 2010; 70(13): 5316-25.
14. Киселева В.И., Крикунова Л.И., Любина Л.В., Безяева Г.П., Панарина Л.В., Куевда Д.А. и др. Количественная нагрузка ВПЧ-16 и прогноз рака шейки матки. В кн.: Покровский В.И., ред. Сборник трудов VII Всероссийской научно-практической конференции с международным участием “Молекулярная диагностика-2010”. т. 3. М.; 2010: 368-70. [Kiseleva V.I., Krikunova L.I., Ljubina L.V., Bezjaeva G.P., Panarina L.V., Kuevda D.A. et al. The quantitative load of HPV-16 and the prognosis of cervical cancer. In the book .: Pokrovsky VI, ed. Collection of Proceedings of the VII All-Russian Scientific and Practical Conference with International Participation “Molecular Diagnostics-2010”. vol. 3. Moscow; 2010: 368-70. (in Russian)]
15. Bergeron C., Ikenberg H., Sideri M., Denton K., Bogers J., Schmidt D. et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015; 123(6): 373-81.
16. Zhou W.Q., Sheng Q.Y., Sheng Y.H., Hou W.J., Xu G.X., Wu Y.M. et al. Expressions of survivin, P16(INK4a), COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application. Eur. J. Gynaecol. Oncol. 2015; 36(1): 62-8.
17. Shukla S., Dass J., Pujani M. p53 and bcl2 expression in malignant and premalignant lesions of uterine cervix and their correlation with human papilloma virus 16 and 18. South Asian J. Cancer. 2014; 3(1): 48-53.
18. Krishnappa P., Mohamad I.B., Lin Y.J., Barua A. Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Diagn. Pathol. 2014; 9: 202.
19. Chang M.S., Oh S., Jung E.J., Park J.H., Jeon H.W., Lee T.S. et al. High-risk human papillomavirus load and biomarkers in cervical intraepithelial neoplasia and cancer. APMIS. 2014; 122(5): 427-36.
20. Vasilescu F., Ceauşu M., Tănase C., Stănculescu R., Vlădescu T., Ceauşu Z. P53, p63 and Ki-67 assessment in HPV-induced cervical neoplasia. Rom. J. Morphol. Embryol. 2009; 50(3): 357-61.
21. Mulvany N.J., Allen D.G., Wilson S.M. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology. 2008; 40(4): 335-44.
22. Xiao W., Bian M., Ma L., Liu J., Chen Y., Yang B. et al. Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions. Acta Cytol. 2010; 54(5): 661-7.
23. Schmidt D. Precancerous lesions of the cervix. Biomarkers in cytological diagnosis. Pathologe. 2011; 32(6): 484-90.
24. Ungureanu C., Socolov D., Anton G., Mihailovici M.S., Teleman S. Immunocytochemical expression of p16INK4a and HPV L1 capsid proteins as predictive markers of the cervical lesions progression risk. Rom. J. Morphol. Embryol. 2010; 51(3): 497-503.
25. Korzeniewski N., Spardy N., Duensing A., Duensing S. Genomic instability and cancer: lessons learned from human papillomavirus. Cancer Lett. 2011; 305(2): 113-22.
26. Nguyen C.L., Münger K. Human papillomavirus E7 protein deregulates mitosis via an association with nuclear mitotic apparatus protein 1. J. Virol. 2009; 83(4): 1700-7.
27. Kivinen K., Taimen P., Kallajoki M. Silencing of Nuclear Mitotic Apparatus protein (NuMA) accelerates the apoptotic disintegration of the nucleus. Apoptosis. 2010; 15(8): 936-45.
28. Apgar B.S., Zoschnick L., Wright T.C. Jr. The 2001 Bethesda system terminology. Am. Fam. Physician. 2003; 68(10): 1992-8.
29. Kurman R.J., Carcangiu M.L., Herrington C.S., Young R. H., eds. WHO Classification of tumours of female reproductive organs. Lyon: IARC; 2014: 169-206.
30. Kaplan K.J., Dainty L.A., Dolinsky B., Rose G.S., Carlson J., McHale M. et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial diagnosed during pregnancy. Cancer Cytopathol. 2004; 102(4): 228-32.
Received 15.05.2017
Accepted 23.06.2017
About the Authors
Ershov V.A., PhD, chief of cytological laboratory of City Clinical Oncology Dispensary.198255, Russia, St.-Petersburg, pr. Veteranov, 56. Tel.: +78127529352, +79523576820. E-mail: ershov@gkod.spb.ru
Lisyanskaya A.S., PhD, chief of gynecological department of City Clinical Oncology Dispensary.
198255, Russia, St.-Petersburg, pr. Veteranov, 56. Tel.: +78127566368. E-mail: goronkod@zdrav.spb.ru
Rongina E.A., oncologist of polyclinical department of City Clinical Oncology Dispensary.
198255, Russia, St.-Petersburg, pr. Veteranov, 56. Tel.: +78122344233. E-mail: goronkod@zdrav.spb.ru
Rakhminova E.R., oncologist of gynecological department of City Clinical Oncology Dispensary.
198255, Russia, St.-Petersburg, pr. Veteranov, 56. Tel.: +78127569858. E-mail: goronkod@zdrav.spb.ru
For citations: Ershov V.A., Lisyanskaya A.S., Ronzhina E.A., Rakhminova E.R. The value of HPV L1 and NuMA1 proteins in the prediction of cervical intraepithelial neoplasia associated with high-risk human papillomavirus. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (11): 63-8. (in Russian)
https://dx.doi.org/10.18565/aig.2017.11.63-68
Similar Articles
